Across TCGA pan-cancer cohorts, ARHGEF15 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ARHGEF15’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARHGEF15 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARHGEF15 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and HNSC are the cancer types where ARHGEF15 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF15 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−1.290	<.001	9	view →
LSCC	Male	All	−1.283	<.001	9	view →
HNSC	All	All	−0.801	<.001	8	view →
PDAC	Male	All	−0.629	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ARHGEF15 RNA expression & survival · all ARHGEF15 data types